• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma

byKathleen Lau
February 25, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study

Punjab launches AI screening program this week

2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]

Tags: bloodblood cancerbortezomibcancerdexamethasonedose limiting toxicityhematologylenalidomidemultiple myelomaoncologypanobinostatperipheral neuropathyrelapsed refractory multiple myeloma
Previous Post

Higher SARS-CoV-2 infection rate in pregnant patients

 Next Post

#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

RelatedReports

Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study

October 13, 2025
Blindness and visual impairment decreasing worldwide
AI Roundup

Punjab launches AI screening program this week

September 30, 2025
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]

September 28, 2025
Variation noted across pre- and post-marketing studies for FDA approved devices
AI Roundup

Artificial intelligence accelerates drug discovery and reduces animal testing

September 12, 2025
Next Post
#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Transdermal estrogen shows similar cardiovascular safety profile to traditional luteinizing hormone therapy in patients with prostate cancer

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Physical Activity, Gut Microbiota, and the Risk of Dyslipidemia in a Community‐Based Cohort Study
  • Aficamten is superior to metoprolol in the management of obstructive hypertrophic cardiomyopathy
  • Limiting antihypertensive use does not reduce mortality in nursing home residents with frailty
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.